Skip to main content
PMC home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 1991 Jun;82(6):732–741. doi: 10.1111/j.1349-7006.1991.tb01910.x

Kinin‐generating Cascade in Advanced Cancer Patients and in vitro Study

Yasuhiro Matsumura 1, Keishi Maruo 1,2, Masami Kimura 1,3, Tetsuro Yamamoto 4, Toshimitsu Konno 3, Hiroshi Maeda 1,✉
PMCID: PMC5918503  PMID: 1906858

Abstract

The role of the bradykinin‐generating system in the pathogenesis of cancer was explored by simultaneously measuring plasma prekallikrein (PK), the precursor of kallikrein, which is the major enzyme responsible for kinin generation, and plasma kininogens (KNG), which are precursors of kinin, in patients with various cancers. The mean value of plasma PK in healthy volunteers was 2.5 ± 0.5 (mean ± SD) units/mg plasma protein and that in cancer patients (all stage IV) was 1.7 ± 0.7 units/ mg plasma protein. The mean value of plasma KNG in healthy volunteers was 12.5 ± 2.0 ng kinin equivalents/mg plasma protein and that in cancer patients was 10.9 ± 2,8 ng. These data showed that plasma PK and plasma KNG values were significantly lower in cancer patients compared with healthy volunteers (P < 0.0005 for PK; 0.0005 < P < 0.005 for KNG; n = 28 for healthy subjects; n = 29 for cancer patients). These data appear to indicate that conversion of PK to kallikrein would probably occur with concomitant consumption of KNG by newly generated kallikrein for kinin generation in cancer patients. Early stage cancer patients showed little difference from healthy volunteers. For the in vitro study, activation of purified Hageman factor (HP) and PK was examined by using cancer cell lines and virus‐transformed cells that produced plasminogen activator (PA) at a high rate. Both HF and PK were activated in the presence of plasminogen. Diploid cell lines and primary fibroblasts, which did not produce PA, activated neither HF nor PK. Taking all these data together, we conclude that kinin generation does occur in the plasma of patients with advanced cancer, and that one of the initiation mechanisms of the kinin‐generating cascade appears to be mediated by plasmin and to depend on cancer cell‐derived PA activity.

Keywords: Bradykinin, Cancer, Vascular permeability, Kallikrein, Plasminogen activater

Full Text

The Full Text of this article is available as a PDF (582.9 KB).

REFERENCES

  • 1. ) Maeda , H. , Takeshita , J. and Kanamaru , R.A lipophilic derivative of neocarzinostatin, A polymer conjugation to an antitumor protein antibiotic . Int. J. Peptide Protein Res. , 14 , 81 – 87 ( 1979. ). [DOI] [PubMed] [Google Scholar]
  • 2. ) Maeda , H. , Matsumura , Y. , Oda , T. and Sasamoto , K.Cancer selective macromolecular therapeusis: tailoring of antitumor protein drugs . In “ Protein‐tailoring for Food and Medical Uses ”, ed. Feeney R. E. and Whitaker J. R. , pp. 353 – 381 ( 1986. ). Marcel Dekker; , New York . [Google Scholar]
  • 3. ) Matsumura , Y. and Maeda , H.A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS . Cancer Res. , 46 , 6387 – 6392 ( 1986. ). [PubMed] [Google Scholar]
  • 4. ) Maeda , H. and Matsumura , Y.Tumoritropic and lymphotropic principle of macromolecular drugs . Crit. Rev. Ther. Drug Carrier Sys. , 6 , 193 – 210 ( 1989. ). [PubMed] [Google Scholar]
  • 5. ) Konno , T. , Maeda , H. , Iwai , K. , Tashiro , S. , Maki , S. , Morinaga , T. , Mochinaga , M. , Hiraoka , T. and Yokoyama , I.Effect of arterial administration of high molecular weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report . Eur. J. Cancer Clin. Oncol. , 19 , 1053 – 1065 ( 1984. ). [DOI] [PubMed] [Google Scholar]
  • 6. ) Konno , T. , Maeda , H. , Iwai , K. , Maki , S. , Tashiro , S. , Uchida , M. and Miyauchi , Y.Selective targeting of anti‐cancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium . Cancer , 54 , 2367 – 2372 ( 1984. ). [DOI] [PubMed] [Google Scholar]
  • 7. ) Iwai , K. , Maeda , H. and Konno , T.Use of oily contrast medium for selective drug targeting to tumor enhanced therapeutic effect and X‐ray image . Cancer Res. , 44 , 2115 – 2121 ( 1984. ). [PubMed] [Google Scholar]
  • 8. ) Iwai , K. , Maeda , H. , Konno , T. , Matsumura , Y. , Yamashita , R. , Yamasaki , K. , Hirayama , S. and Miyauchi , Y.Tumor targeting by arterial administration of lipids: rabbit model with VX2 carcinoma in the liver . Anticancer Res. , 7 , 321 – 328 ( 1987. ). [PubMed] [Google Scholar]
  • 9. ) Matsumura , Y. , Kimura , M. , Yamamoto , T. and Maeda , H.Involvement of the kinin‐generating cascade in enhanced vascular permeability in tumor tissue . Jpn. J. Cancer Res. , 79 , 1327 – 1334 ( 1988. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. ) Maeda , H. , Matsumura , Y. and Kato , H.Purification and identification of hydroxyprolyl3‐bradykinin in ascitic fluid from a patient with gastric cancer . J. Biol. Chem. , 263 , 16051 – 16054 ( 1988. ). [PubMed] [Google Scholar]
  • 11. ) Margolius , J.The interrelationship of coagulation of plasma and release of peptides . Ann. N.Y. Acad. Sci. , 104 , 133 – 145 ( 1963. ). [DOI] [PubMed] [Google Scholar]
  • 12. ) Jacobsen , S.Substrates for plasma kinin‐forming enzymes in human, dog and rabbit plasmas . Br. J. Pharmacol. , 26 , 403 – 411 ( 1966. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. ) Lorand , L.HMW and LMW kininogens . Methods Enzymol. , 80 , 172 – 198 ( 1981. ). [DOI] [PubMed] [Google Scholar]
  • 14. ) Erdös , E. G.Enzymes that inactivate active polypeptides . Biochem. Pharmacol. , 8 , 112 – 118 ( 1961. ). [Google Scholar]
  • 15. ) Sheikh , I. A. and Kapalan , A. P.Mechanism of digestion of bradykinin and lysylbradykinin (kallidin) in human serum; role of carboxypeptidase, angiotensin‐converting enzyme and determination of final degradation products . Biochem. Pharmacol. , 38 , 993 – 1000 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 16. ) Matsumura , Y. , Maeda , H. and Kato , H.Degradation pathway of kinins in tumor ascites and inhibition by kininase inhibitors: analysis by HPLC . Agents Actions , 29 , 172 – 180 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 17. ) Fujikawa , K. and Davie , E. W.Human factor XII (Hageman factor) . Methods Enzymol. , 80 , 198 – 211 ( 1981. ). [DOI] [PubMed] [Google Scholar]
  • 18. ) Yamamoto , T. , Kozono , K. , Okamoto , T. , Kato , H. and Kambara , T.Purification of guinea‐pig plasma prekailikrem: activation by prekallikrein activator derived from guinea‐pig skin . Biochim. Biophys. Acta , 614 , 511 – 525 ( 1980. ). [DOI] [PubMed] [Google Scholar]
  • 19. ) Quigley , J. P. , Ossowski , L. and Reich , E.Plasminogen, the serum proenzyme activated by factors from cells transformed by oncogenic viruses . J. Biol. Chem. , 249 , 4306 – 4311 ( 1974. ). [PubMed] [Google Scholar]
  • 20. ) Oh‐ishi , S. and Katori , M.Fluorometric assay for plasma prekallikrein using peptidyl‐methylcoumarinylamide as a substrate . Thromb. Res. , 14 , 551 – 559 ( 1979. ). [DOI] [PubMed] [Google Scholar]
  • 21. ) Molla , A. , Yamamoto , T. , Akaike , T. , Miyoshi , S. and Maeda , H.Activation of Hageman factor and prekallikrein and generation of kinin by various microbial proteinases . J. Biol. Chem. , 264 , 10589 – 10594 ( 1989. ). [PubMed] [Google Scholar]
  • 22. ) Ueno , A. , Oh‐ishi , S. , Kitagawa , T. and Katori , M.Enzyme immunoassay of bradykinin using β‐d‐galactosidase as a labelling enzyme , Biochem. Pharmacol. , 30 , 1659 – 1664 ( 1981. ). [DOI] [PubMed] [Google Scholar]
  • 23. ) Kurooka , S. , Kaibe , K. , Ueyama , H , Kido , K. , Matsumura , Y. , Maeda , H. and Kato , H.The specific determination of hydroxyproly3‐bradykinin using a competitive binding enzyme immunoassay . J. Immunol. Methods , 118 , 147 – 149 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 24. ) Maeda , H. , Ishida , N. , Kawauchi , H. and Tsuzimura , K.Reaction of fluoresceinisothiocyanate with proteins and amino acids. I. Covalent and non‐covalent binding . J. Biochem. , 65 , 777 – 783 ( 1969. ). [DOI] [PubMed] [Google Scholar]
  • 25. ) Pouneau‐Schneider , N. , Delori , P. , Boutüre , B. , Arnoux , D. , George , F. , Sampol , J. and Martin , P. M.Modulation of plasminogen activator systems by matrix components in two breast cancer cell lines: MCF‐7 and MDA‐MB‐231 . J. Natl. Cancer Inst. , 81 , 259 – 266 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 26. ) Angeles‐Cano , E.A spectrophotometric solid‐phase fibrin‐tissue plasminogen activator assay (SOFIA‐tPA) for high‐fibrin‐affinity tissue plasminogen activators . Anal. Biochem. , 153 , 201 – 210 ( 1986. ). [DOI] [PubMed] [Google Scholar]
  • 27. ) Lowry , O. H. , Rosebrough , N. J. , Farr , A. L. and Randall , R.J. Protein measurement with the Folin phenol reagent . J. Biol. Chem. , 193 , 265 – 275 ( 1951. ). [PubMed] [Google Scholar]
  • 28. ) Peterson , H. I. and Appelgren , K. L.Experimental studies on the uptake and retention of labelled proteins in a rat . Eur. J. Cancer , 9 , 543 – 547 ( 1972. ). [DOI] [PubMed] [Google Scholar]
  • 29. ) Dvorak , H. F. , Orenstein , N. S. , Carvalho , A. C. , Churchill , W. H. , Dvorak , A. M , Galli , S. J , Feder , J. , Bitzer , A. M. , Rypysc , J. and Giovinco , P.Induction of a fibrin gel investment: an early event in Line 10 hepatocarcinoma growth mediated by tumor‐secreted products . J. Immunol. , 122 , 166 – 174 ( 1979. ). [PubMed] [Google Scholar]
  • 30. ) Senger , D. R. , Galli , S. J. , Dvorak , A. M. , Perruzi , C. A. , Harvey , V. S. and Dvorak , H. F.Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid . Science , 219 , 983 – 985 ( 1983. ). [DOI] [PubMed] [Google Scholar]
  • 31. ) Fleck , A. , Raines , G. , Hawker , F. , Trotter , J. , Wallace , P. I. , Ledingham , I. M. and Caiman , K. C.Increased vascular permeability: a major cause of hypoalbuminaemia in disease and injury . Lancet , i , 781 – 784 ( 1985. ). [DOI] [PubMed] [Google Scholar]
  • 32. ) Dvorak , H. F. , Senger , D. R. , Dvorak , A. M. , Harvey , V. S. and McDonagh , J.Regulation of extravascular coagulation by microvascular permeability . Science , 227 , 1059 – 1061 ( 1985. ). [DOI] [PubMed] [Google Scholar]
  • 33. ) Greenbaum , L. M. , Grebom , P. , Johnston , M. , Prakash , A. and Semente , G.Pepstatin – an inhibitor of leukokinin formation and ascitic fluid accumulation . Cancer Res. , 35 , 706 – 710 ( 1975. ). [PubMed] [Google Scholar]
  • 34. ) Maeda , H. and Molla , A.Pathogenic potentials of bacterial proteases . Clin. Chim. Acta , 185 , 357 – 368 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 35. ) Matsumoto , K. , Yamamoto , T. , Kamata , R. and Maeda , H.Pathogenesis of serratial infection: activation of the Hageman factor‐prekallikrein cascade by serratial protease . J. Biochem. , 96 , 739 – 749 ( 1984. ). [DOI] [PubMed] [Google Scholar]
  • 36. ) Mason , J. W , Kleeberg , U. , Dolan , P. and Colman , R. W.Plasma kallikrein activation and Hageman factor in Gram‐negative bacteria . Ann. Intern. Med. , 73 , 545 – 547 ( 1970. ). [DOI] [PubMed] [Google Scholar]
  • 37. ) Yamada , T. , Harber , P. , Pettit , G. W. , Wing , D. A. and Oster , C. N.Activation of the kallikrein‐kinin system in Rocky Mountain spotted fever . Ann. Intern. Med. , 88 , 764 – 768 ( 1978. ). [DOI] [PubMed] [Google Scholar]
  • 38. ) Markus , G. , Takita , H. , Camiolo , S. M. , Carsanti , J. G. , Everts , J. L. and Hobika , H.Content and characterization of plasminogen activators in human lung tissue . Cancer Res. , 40 , 841 – 848 ( 1980. ). [PubMed] [Google Scholar]
  • 39. ) Kirchheimen , J. C. , Roller , A. and Binder , B. R.Isolation and characterization of plasminogen activators from hyperplastic and malignant prostate tissue . Biochim. Biophys. Acta , 797 , 256 – 265 ( 1984. ). [DOI] [PubMed] [Google Scholar]
  • 40. ) Tissot , J. D. , Hauert , J. and Bachmann , F.Characterization of plasminogen activators from normal human breast and colon and from breast and colon carcinomas . Int. J. Cancer , 34 , 295 – 302 ( 1984. ). [DOI] [PubMed] [Google Scholar]
  • 41. ) Lang , W. , Jones , P. and Benedict , W.Relationship between fibrinolysis of cultured cells and malignancy . J. Natl. Cancer Inst , 54 , 173 – 179 ( 1975. ). [DOI] [PubMed] [Google Scholar]
  • 42. ) Duffy , M. J. and O'Grudy , P.Plasminogen activator and cancer . Eur. J. Cancer Clin. Oncol. , 20 , 577 – 582 ( 1984. ). [DOI] [PubMed] [Google Scholar]
  • 43. ) Folkman , J. and Cotran , R.Relation of vascular proliferation to growth . Int. Rev. Exp. Pathol. , 16 , 207 – 248 ( 1976. ). [PubMed] [Google Scholar]
  • 44. ) Folkman , J. and Handenschild , C.Angiogenesis in vitro . Nature , 288 , 551 – 556 ( 1980. ). [DOI] [PubMed] [Google Scholar]
  • 45. ) Tarin , D. , Hoyt , B. J. and Evans , D. J.Correlation of collagenase secretion with metastatic colonization potential in naturally occurring marine mammary tumors . Br. J. Cancer , 46 , 266 ( 1982. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46. ) Damø , K. , Andreasen , P. A. , Grandahl‐Hansen , J. , Kristensen , P. , Nielsen , L. S. and Slcriver , L.Plasminogen activators, tissue degradation, and cancer . Adv. Cancer Res. , 44 , 139 – 266 ( 1985. ). [DOI] [PubMed] [Google Scholar]
  • 47. ) Colman , R. W.Surface‐mediated defence reactions: the plasma contact activation system . J. Clin. Invest. , 73 , 1249 – 1253 ( 1984. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48. ) Kaplan , A. P. and Silverberg , M.The coagulation‐kinin pathway of human plasma . Blood , 70 , 1 – 15 ( 1987. ). [PubMed] [Google Scholar]
  • 49. ) Kozin , F. and Cochrane , C. G.The contact activation system of plasma: biochemistry and pathophysiology . In “ Inflammation: Basic Principles and Clinical Correlates ”, ed. Gallin J. I. , Goldstein I. M. and Snyderman R. , pp. 101 – 120 ( 1988. ), Raven Press; , New York . [Google Scholar]
  • 50. ) Fujikawa , K. , Heimark , P. L. , Kurachi , K. and Davie , E. W.Activation of bovine factor XII (Hageman factor) by plasma kallikrein . Biochemistry , 19 , 1322 – 1330 ( 1980. ). [DOI] [PubMed] [Google Scholar]
  • 51. ) Hasui , Y. , Suzumiya , J. , Marutsuka , K. , Sumiyoshi , A. , Hashida , S. and Ishikawa , E.Comparative study of plasminogen activators in cancers and normal mucosa of human urinary bladder . Cancer Res. , 49 , 1067 – 1070 ( 1989. ). [PubMed] [Google Scholar]
  • 52. ) Takada , A. , Takada , Y. and Sugawara , Y.Effects of fibrinogen and fibrin on the activation of Glu‐ and Lysplasminogen by urokinase . Thromb. Res. , 33 , 561 – 569 ( 1984. ). [DOI] [PubMed] [Google Scholar]
  • 53. ) Camiolo , S. M. , Thorsen , S. and Astrup , T.Fibrino‐genolysis and fibrinolysis with tissue plasminogen activator, urokinase, streptokinase‐activated human globulin, and plasmin . Proc. Soc. Exp. Biol Med. , 138 , 277 – 280 ( 1971. ). [DOI] [PubMed] [Google Scholar]
  • 54. ) O'Meara , R. A. Q. and Tackson , R. D.Cytological observations on carcinoma . Isr. J. Med. Sci. , 6 , 327 – 328 ( 1958. ). [DOI] [PubMed] [Google Scholar]
  • 55. ) Hiramoto , R. , Bernecky , J. , Jurdndowski , J. and Pressman , D.Fibrin in human tumors . Cancer Res. , 20 , 592 – 593 ( 1960. ). [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES